B-cell prolymphocytic leukemia other diagnostic studies: Difference between revisions
Carlos Lopez (talk | contribs) No edit summary |
Carlos Lopez (talk | contribs) No edit summary |
||
Line 8: | Line 8: | ||
==Immunophenotyping== | ==Immunophenotyping== | ||
The flow cytometric immunophenotyping indicates that the most common malignant cells are positive for:<ref name=PLL>{{cite web | title = National Cancer Institute| url =http://seer.cancer.gov/seertools/hemelymph/51f6cf58e3e27c3994bd53f9/}}</ref> | The flow cytometric [[immunophenotyping]] indicates that the most common malignant cells are positive for:<ref name=PLL>{{cite web | title = National Cancer Institute| url =http://seer.cancer.gov/seertools/hemelymph/51f6cf58e3e27c3994bd53f9/}}</ref> | ||
* CD20 | * CD20 |
Revision as of 14:50, 6 October 2015
B-cell prolymphocytic leukemia |
Differentiating B-cell prolymphocytic leukemia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
B-cell prolymphocytic leukemia other diagnostic studies On the Web |
American Roentgen Ray Society Images of B-cell prolymphocytic leukemia other diagnostic studies |
FDA on B-cell prolymphocytic leukemia other diagnostic studies |
CDC on B-cell prolymphocytic leukemia other diagnostic studies |
B-cell prolymphocytic leukemia other diagnostic studies in the news |
Blogs on B-cell prolymphocytic leukemia other diagnostic studies |
Directions to Hospitals Treating B-cell prolymphocytic leukemia |
Risk calculators and risk factors for B-cell prolymphocytic leukemia other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Carlos A Lopez, M.D. [2]
Overview
Other diagnostic studies for acute lymphoblastic leukemia include Immunophenotyping.
Immunophenotyping
The flow cytometric immunophenotyping indicates that the most common malignant cells are positive for:[1]
- CD20
- CD22
- CD23
- CD79a
- CD79b
- FMC7
- Strong surface IgM +/- IgD